tbuckley/cabot-search huggingface dataset:
Pomalidomide Inhibits PD-L1 Induction to Promote Antitumor Immunity
Authors: Yuki Fujiwara, Yi Sun, Robert J. Torphy, Jiadai He, Katsuhiko Yanaga, Barish H. Edil, Richard D. Schulick, Yuwen Zhu
Journal: Cancer Research (2018)

Abstract Thalidomide-like drugs have been approved for the treatment of human multiple myeloma, with their direct antitumor effects and immunomodulatory functions well documented. However, the exact molecular mechanisms that govern these effects remain unclear. Here we demonstrate that pomalidomide promotes immune response by inhibiting expression of PD-L1. Pomalidomide inhibited PD-L1 expression on tumor cells to promote CTL activity in vitro and suppressed PD-L1 upregulation on antigen-presenting cells to prevent peptide-induced T-cell tolerance. Knockout of PD-L1 on tumor cells or in mice completely eliminated the immunomodulatory effect of pomalidomide. Furthermore, pomalidomide synergized with other immunotherapies to improve anticancer therapy. Taken together, this study identifies a new mechanism for the immunomodulatory functions of pomalidomide in cancer therapy. These results also offer a clinical approach for blocking PD-L1 induction and potentially promoting antitumor immunity. Significance: These findings report that the immunomodulatory drug pomalidomide, widely used to treat myeloma and other cancers, enhances antitumor immunity by inhibiting PD-1/PD-L1 expression.
A randomized phase III study of denosumab before curettage for giant cell tumor of bone: Japan Clinical Oncology Group study JCOG1610
Authors: H. Urakawa, J. Mizusawa, K. Tanaka, J. Eba, H. Hiraga, M. Hosaka, A. Kawai, F. Nakatani, E. Kobayashi, Y. Nishida, T. Okamoto, T. Matsunobu, Y. Iwamoto, H. Fukuda, T. Ozaki
Journal: Annals of Oncology (2018)
Abstract 19408: Multiple Biomarker Approach Predicts Increasing Risk of Recurrent CV Events in Patients With Diabetes Mellitus in the EXAMINE Randomized Trial
Authors: Erin A Bohula, Christopher P Cannon, William B White, Petr Jarolim, Brian A Bergmark, Stuart Kupfer, Marc P Bonaca, Yuyin Liu, Faiez Zannad, David A Morrow
Journal: Circulation (2016)

Introduction: Patients with diabetes and recent acute coronary syndrome (ACS) have a significant but heterogeneous risk of recurrent cardiovascular (CV) events. Hypothesis: We hypothesized that a m...
Potent natural killer (NK) and myeloid blood cell remodeling by cabozantinib (Cabo) in pre-treated metastatic renal cell carcinoma (mRCC) patients (pts)
Authors: E. Verzoni, S. Ferro, G. Procopio, A. Cova, R. Ratta, A. Raimondi, P. Sepe, P. Squarcina, L. Lalli, V. Huber, D. Rinchai, D. Bedognetti, L. Rivoltini
Journal: Annals of Oncology (2018)
Clinical Implications of Real-time and Intermittently Scanned Continuous Glucose Monitoring
Authors: Steven V. Edelman, Nicholas B. Argento, Jeremy Pettus, Irl B. Hirsch
Journal: Diabetes Care (2018)

Two types of continuous glucose monitoring (CGM) systems are now available: real-time CGM (rtCGM) and intermittently scanned (isCGM). Current rtCGM systems automatically transmit a continuous stream of glucose data to the user, provide alerts and active alarms, and transmit glucose data (trend and numerical) in real time to a receiver, smart watch, or smartphone. The current isCGM system provides the same type of glucose data but requires the user to purposely scan the sensor to obtain information, and it does not have alerts and alarms. Both CGM technologies have significant advantages over self-monitoring of blood glucose; however, differences in the features and capabilities of the two approaches must be considered when guiding patient selection of the system that meets their individual needs.
P3.13-29 Patient-Derived Xenograft Models(PDX) of Lung Squamous Cell Carcinoma(SCC) for Preclinical Studies
Authors: T.H. Kim, J. Lee, B. Park, H.K. Kim, J. Lee, E. Hwang, H. Lee, K. Koo, H. Lee, S. Lee, H. Rhee, J.E. Lee, Y. Choi, J. Kim
Journal: Journal of Thoracic Oncology (2018)
Totally implantable venous access port: A prospective long-term study of early and late complications in adult patients with cancer.
Authors: Pauline du Rusquec, Eric Voog, Loic Campion, Hugues Pierre Bourgeois, Fabrice Denis, Olivier Dupuis, Gerard Ganem, Cedrik Lafond, Katell Le Du, Sophie Roche Forestier, Philippe Solal-Celigny
Journal: Journal of Clinical Oncology (2014)

e20635 Background: The main complications caused by Totally Implantable Venous Access Port (TIVAP) for chemotherapy are infections and thromboembolic events. However, only a limited amount of data is available on the overall safety and tolerance of TIVAP. We conducted a prospective study of early and long term adverse events in order to better appreciate the overall tolerance and to research and pinpoint risk factors in a chemotherapy-treated population. Methods: A prospective single-center observational study was conducted in Clinique Victor Hugo, Le Mans (France). All adult patients with cancer who had a TIVAP implanted between January 1st and December 31st 2006 were registered. Early and late complications were recorded until removal of the device, patient's death or until December 31st 2013. Cancer type and staging, any thrombotic history, antiplatelet agent or anticoagulant therapy, surgeon experience, site of insertion, and type of chemotherapy were recorded. Results: TIVAPs were implanted for 467 patients (mean age, 62 years, range, 18-88), for cancer treatment. The median follow-up was 18 months (1-94) in 371634 catheter-days. 87 complications were recorded (0.23/1000 days of use/observation): 39 infections (8.35%), 16 thrombotic events around catheter (3.43%), 23 malfunctions (4.93%) and 9 extravasations (1.93%).In a multivariate analysis, subjects aged 75 and over ( Hazard Ratio (HR) = 1.85, 95% CI, 1.10 to 3.09; P=0.019), and cancer sites other than breast (HR = 1.87; 95% CI, 1.08 to 3.23; P=0.025), were significantly associated with a higher risk of complications. For infection, HR were 2.44 (95% CI, 1.15 to 5.18; P=0.020) and 2.66 (95%CI 1.08 to 6.54; p=0.033) respectively. The cancer stage, any thrombotic history, antiplatelet agent or anticoagulant therapy, surgeon experience, location of catheter or type of chemotherapy had no significant effect upon risk incidence for adverse events. Conclusions: This study is the largest longitudinal study conducted in patients with TIVAP and also has the longest follow-up. Our results confirm that TIVAP carries a low risk of complications. Adverse events were especially rare in patients with breast cancer or aged less than 75 years.
Serum levels of the adipokine zinc-alpha2-glycoprotein (ZAG) predict mortality in hemodialysis patients
Authors: Anaïs Bouchara, Dan Yi, Myriam Pastural, Samuel Granjon, Jean-Christophe Selag, Maurice Laville, Walid Arkouche, Solenne Pelletier, Denis Fouque, Christophe O. Soulage, Laetitia Koppe
Journal: Kidney International (2018)
Clinical activity, safety, and PK/PD from a phase I study of RO6874281, a fibroblast activation protein (FAP) targeted interleukin-2 variant (IL-2v)
Authors: I. Melero, E. Castanon Alvarez, M. Mau-Sorensen, U.N. Lassen, M.P. Lolkema, D.G. Robbrecht, C.A. Gomez-Roca, J. Martin-Liberal, J. Tabernero, W. Ros, S. Ahmed, N. Isambert, H. Piper Lepoutre, C. Boetsch, J. Charo, S. Evers, V. Teichgräber, J.H.M. Schellens
Journal: Annals of Oncology (2018)
GW29-e1966 Renal Autotransplantation for the Treatment of Renovascular Hypertension caused by Complex Renal Artery Fibromuscular Dysplasia: A case report and review of the literature
Authors: Jiang He, Bingbo Yu, Wenhao Xia, Chen Su, Xiaoyu Zhang, Jun Tao
Journal: Journal of the American College of Cardiology (2018)
Identification of biological axes associated with stage II/III CRC recurrence risk and outcome after adjuvant therapy revealed a T-effector-independent prognostic role for granzyme B
Authors: M. Das Thakur, A. Udyavar, T. Sandmann, C. Li, L.J.W. Bosch, W. O’Gorman, Y. Li, A. Au-Yeung, C. Takahashi, R. Bourgon, A. Daemen, P. Hegde, C. Bais
Journal: Annals of Oncology (2018)
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
Authors: Asim Amin, Elizabeth R Plimack, Marc S Ernstoff, Lionel D Lewis, Todd M Bauer, David F McDermott, Michael Carducci, Christian Kollmannsberger, Brian I Rini, Daniel Y C Heng, Jennifer Knox, Martin H Voss, Jennifer Spratlin, Elmer Berghorn, Lingfeng Yang, Hans J Hammers
Journal: Journal for ImmunoTherapy of Cancer (2018)

Combination treatment with immune checkpoint inhibitors and antiangiogenic drugs has shown encouraging preliminary antitumor activity across various tumor types including advanced or metastatic renal cell carcinoma (aRCC). The open-label, parallel-cohort, dose-escalation, phase I CheckMate 016 study evaluated the efficacy and safety of nivolumab in combination with antiangiogenic tyrosine kinase inhibitors or ipilimumab. Long-term outcomes from this study for the combination of nivolumab plus sunitinib or pazopanib in aRCC are presented.Patients with aRCC received nivolumab plus either sunitinib (50 mg/day, 4 weeks on/2 weeks off; N + S) or pazopanib (800 mg/day; N + P) until progression/unacceptable toxicity. The nivolumab starting dose was 2 mg/kg every 3 weeks, with planned escalation to 5 mg/kg every 3 weeks. Primary endpoints were safety and tolerability; antitumor activity was a secondary endpoint.Arm N + S enrolled 33 patients, 19 of whom were treatment-naïve; this arm advanced to the expansion phase. Median follow-up was 50.0 months. Patients experienced high frequencies of adverse events (AEs) including treatment-related AEs (100%), grade 3/4 treatment-related AEs (82%), and treatment-related AEs leading to discontinuation (39%). Investigator-assessed objective response rate (ORR) was 55% (18/33) and median progression-free survival (PFS) was 12.7 months. Median overall survival (OS) was not reached. Arm N + P enrolled 20 patients, all had ≥1 prior systemic therapy; this arm was closed due to dose-limiting toxicities and did not proceed to expansion. Median follow-up was 27.1 months. Patients treated with N + P experienced high frequencies of AEs including treatment-related AEs (100%), grade 3/4 treatment-related AEs (70%), and treatment-related AEs leading to discontinuation (25%). Investigator-assessed ORR was 45% (9/20) and median PFS was 7.2 months. Median OS was 27.9 months.The addition of standard doses of sunitinib or pazopanib to nivolumab resulted in a high incidence of high-grade toxicities limiting future development of either combination regimen. While there was no adverse impact on response and the OS outcome was notable, the findings suggest that the success of combination regimens based on immune checkpoint inhibitors and antiangiogenic drugs may be dependent on careful selection of the antiangiogenic component and dose.Clinicaltrials.gov identifier: NCT01472081 . Registered 16 November 2011.
Unexpected Bone Metastases in 99mTc-Pertechnetate Scan of Recurrent Goiter
Authors: Sebastian Hoberück, Enrico Michler, Danilo Seppelt, Jörg Kotzerke, Claudia Brogsitter
Journal: Clinical Nuclear Medicine (2018)

Abstract A 68-year-old woman who underwent a thyroidectomy for bilateral goiter 20 years ago was referred to our department. The examination revealed a newly occurred thyroid nodule in the right central lobe. Unexpectedly the 99m Tc-pertechnetate scan revealed several extrathyroidal foci right-sided supraclavicular, beside a cold thyroid nodule in the right lower lobe. Consecutive surgery and histology confirmed the suspected diagnosis of follicular thyroid cancer with multiple bone metastases. Whole-body scintigraphy performed after the following radioiodine therapy indicated disseminated osseous metastases.
Remaining Positive About Positive Psychological Interventions for Pain
Authors: Afton L. Hassett
Journal: JAMA Network Open (2018)

Leslie R. M. Hausmann, PhD; Ada Youk, PhD; C. Kent Kwoh, MD; Rollin M. Gallagher, MD, MPH; Debra K. Weiner, MD; Ernest R. Vina, MD, MS; D. Scott Obrosky, MS; Genna T. Mauro, BS; Shauna McInnes, BS; Said A. Ibrahim, MD, MPH, MBA
Phase I studies assessing the safety and clinical activity of multiple doses of a NKG2D-based CAR-T therapy, CYAD-01, in metastatic colorectal cancer
Authors: A. Flament, A. Hendlisz, L. Shaza, S. Aspeslagh, M. Vouche, V. Donckier, A. Awada, J.-P. Machiels, M. van den Eynde, J.-L. Canon, J. Carrasco, C. Lonez, F.F. Lehmann
Journal: Annals of Oncology (2018)
Addressing Intimate Partner Violence and Abuse of Older or Vulnerable Adults in the Health Care Setting—Beyond Screening
Authors: Elizabeth Miller, Scott R. Beach, Rebecca C. Thurston
Journal: JAMA Internal Medicine (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Match-adjusted indirect comparison of durvalumab and chemotherapy for locally advanced or metastatic urothelial carcinoma (UC) following failure of platinum-based therapy
Authors: C.K. Hoyle, A.B. Klein, K.A. Patel, N. Shire, H. Wang, B.C. Chu, M. Ouwens, B.L. Nordstrom, L. Horne, H.-T. Arkenau
Journal: Annals of Oncology (2018)
GW29-e0157 Attenuation of High Glucose-Induced Rat Cardiomyocyte Apoptosis by Exendin-4 via Intervention of HO-1/Nrf-2 and the PI3K/AKT Signaling Pathway
Authors: Shumei Zhao, Chunyan Guo
Journal: Journal of the American College of Cardiology (2018)
The value of European immigration for high-level UK research and clinical care: cross-sectional study
Authors: Mursheda Begum, Grant Lewison, Mark Lawler, Richard Sullivan
Journal: Journal of the Royal Society of Medicine (2018)

Summary Objective The UK’s impending departure (‘Brexit’) from the European Union may lead to restrictions on the immigration of scientists and medical personnel to the UK. We examined how many senior scientists and clinicians were from other countries, particularly from Europe, in two time periods. Design Cross-sectional study. Setting United Kingdom. Participants Individuals who had been elected as Fellows of the Royal Society or of the Academy of Medical Sciences, and UK medical doctors currently practising and listed in the Medical Register for 2015. Main outcome measures Percentages of Fellows of the Royal Society, Fellows of the Academy of Medical Sciences and UK medical doctors by nationality (UK and Irish: UKI, European: EUR and rest of world: RoW) over time. Fellows of the Royal Society and the Academy of Medical Sciences proportions were assessed for two time periods, and doctors over decades of qualification (&lt;1960s to 2010s). Results Percentages of European Fellows of the Royal Society increased from 0.8% (1952–1992) (the year the UK signed the Maastricht treaty) to 4.3% (1993–2015). For Fellows of the Academy of Medical Sciences, percentages increased from 2.6% (pre-1992) to 8.9% (post-1992) (for both, p &lt; 0.001). In the 1970s, only 6% of doctors were trained in the EU; the proportion increased to 11% in the last two decades (also p &lt; 0.001). Europeans replaced South Asians as the main immigrant group. Among these, doctors from the Czech Republic, Greece, Poland and Romania made the largest contribution. Conclusions Any post-Brexit restriction on the ability of the UK to attract European researchers and medical doctors may have serious implications for the UK’s science leadership globally and healthcare provision locally.
OPINION: A single-arm, open-label, phase IIIb study of olaparib maintenance monotherapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) and without germline BRCA mutations (non-gBRCAm)
Authors: A.M. Poveda, R. Davidson, C. Blakeley, A. Milner
Journal: Annals of Oncology (2018)
Effect of exosomal miRNA on cancer biology and clinical applications
Authors: Zhenqiang Sun, Ke Shi, Shuaixi Yang, Jinbo Liu, Quanbo Zhou, Guixian Wang, Junmin Song, Zhen Li, Zhiyong Zhang, Weitang Yuan
Journal: Molecular Cancer (2018)

Exosomes, extracellular vesicles with diameters ranging from 30 to 150 nm, are widely present in various body fluids. Recently, microRNAs (miRNAs) have been identified in exosomes, the biogenesis, release, and uptake of which may involve the endosomal sorting complex required for transport (ESCRT complex) and relevant proteins. After release, exosomes are taken up by neighboring or distant cells, and the miRNAs contained within modulate such processes as interfering with tumor immunity and the microenvironment, possibly facilitating tumor growth, invasion, metastasis, angiogenesis and drug resistance. Therefore, exosomal miRNAs have a significant function in regulating cancer progression. Here, we briefly review recent findings regarding tumor-derived exosomes, including RNA sorting and delivering mechanism. We then describe the intercommunication occurring between different cells via exosomal miRNAs in tumor microenvironmnt, with impacts on tumor proliferation, vascularization, metastasis and other biological characteristics. Finally, we highlight the potential role of these molecules as biomarkers in cancer diagnosis and prognosis and tumor resistance to therapeutics.
Cancer Survivorship and Employment: Intersection of Oral Agents, Changing Workforce Dynamics, and Employers’ Perspectives
Authors: Cathy J Bradley, Kelsey L Brown, Michelle Haan, Russell E Glasgow, Lee S Newman, Borsika Rabin, Debra P Ritzwoller, Liliana Tenney
Journal: JNCI Journal of the National Cancer Institute (2018)

The ability to continue employment during and following cancer diagnosis and treatment is critical to working-age cancer survivors. Prolonged survival combined with concerns of the financial burden associated with high-cost therapies makes the mitigation of work-related consequences all the more relevant, particularly in light of recent workforce trends and evolving employment dynamics. Research that integrates the needs of survivors, employers, and the workforce is required so that advancements are made to support employed cancer survivors. In this commentary, we present four priorities for research to advance what is known about the employment effects of cancer: 1) data needed to understand the impact of emerging treatments and their influence on employment and job performance; 2) cancer survivors in the changing work environment with respect to contractual arrangements and employment in small and medium-sized firms; 3) employers' perspectives and approaches to implementing workplace policies for cancer survivors; and 4) the development of feasible, scalable, and sustainable workplace interventions that can be implemented to address these issues. The confluence of these factors makes a strong argument for research to advance what is known and what can be done about the employment consequences of cancer.
Abstract 15748: Alirocumab Efficacy and Safety by Race and Ethnicity: Analysis From Three ODYSSEY Phase 3 Trials
Authors: Keith C Ferdinand, Terry A Jacobson, Kim A Williams, Andrew T Koren, Joseph Elassal, Desmond E Thompson, Prakash Deedwania
Journal: Circulation (2017)

Background: Differences in lipids and cardiovascular disease risk profiles have been observed in African American/Black (AA/B) vs White (W), and Hispanic/Latino (H/L) of any race vs non-H/L populat...
New onset atrial fibrillation, prominent chest wall veins, and dyspnoea
Authors: Charlotte Marriott, Christopher George
Journal: BMJ (2018)

A 74 year old man presented with palpitations concurrent with new onset atrial fibrillation. He also complained of increasingly visible markings on his chest and occasional breathlessness on waking.

His comorbidities included chronic obstructive pulmonary disease and hypertension with left ventricular hypertrophy.

On examination, he had prominent vessels over his chest wall but nothing else of note. He underwent chest radiography (fig 1)



Fig 1 
Chest radiograph



What is the most likely diagnosis?

A large retrosternal goitre causing venous and tracheal compression, with atrial fibrillation secondary to hyperthyroidism.

Retrosternal goitres are anterior mediastinal masses (anterior to the pericardium and great vessels), and can usually be distinguished on plain film from posterior mediastinal …
Review: Bioengineering approach for the repair and regeneration of peripheral nerve
Authors: Joshua Moskow, Bryan Ferrigno, Nikhil Mistry, Devina Jaiswal, Ketan Bulsara, Swetha Rudraiah, Sangamesh G. Kumbar
Journal: Bioactive Materials (2018)

Complex craniofacial surgeries of damaged tissues have several limitations, which present complications and challenges when trying to replicate facial function and structure. Traditional treatment techniques have shown suitable nerve function regeneration with various drawbacks. As technology continues to advance, new methods have been explored in order to regenerate damaged nerves in an effort to more efficiently and effectively regain original function and structure. This article will summarize recent bioengineering strategies involving biodegradable composite scaffolds, bioactive factors, and external stimuli alone or in combination to support peripheral nerve regeneration. Particular emphasis is made on the contributions of growth factors and electrical stimulation on the regenerative process.
Weaning From Mechanical Ventilation
Authors: Laveena Munshi, Niall D. Ferguson
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Genetic variations within the HER3 gene predict outcome for mCRC patients treated with first-line FOLFIRI/bevacizumab or FOLFIRI/cetuximab: Data from FIRE-3
Authors: M.D. Berger, S. Stintzing, V. Heinemann, S. Cao, D. Yang, Y. Miyamoto, M. Suenaga, D.L. Hanna, S. Soni, A. Puccini, R. Tokunaga, M. Naseem, F. Battaglin, M. McSkane, W. Zhang, H.-J. Lenz
Journal: Annals of Oncology (2018)